

Research Reference Sheet

The highlighted **blue word** is the clinical study title. This section describes the name given to the clinical study.

Clinical Trials: Brain Cancer

Regional Health is involved in brain cancer research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 719-2300.

NCCTG N0872: Phase I/II Study of Dasatinib/Bevacizumab in Recurrent Glioblastoma

The **purpose** section provides background information and discusses the objective of the trial.

PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of dasatinib when given together with bevacizumab and to see how well it works compared to placebo in treating patients with recurrent or progressive high-grade glioma or glioblastoma multiforme.

To learn more, contact:

[John T. Vucurevich](#)
[Regional Cancer](#)
[Care Institute](#)

(605) 719-2300

Principal Investigators



[Richard Tenglin, MD](#)
Medical Oncologist



[Michael Swartz, MD](#)
Radiation Oncologist

The **phone numbers** listed within the study are there if you have questions or need to discuss the clinical trial.

The **Principal Investigator(s)** listed in the study are the doctor(s) that will be responsible for conducting the clinical study.

